Starting May 1, 2018, most imported drugs, particularly anticancer drugs, are available tariff-free in China. On October 10, 2018, medical insurance began to cover 17 additional anticancer drugs. The newly negotiated drug prices are on average more than 50 percent lower, and the payment rates for most imported drugs after negotiation are lower than the market prices in surrounding countries and regions.